LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)
Sherene Loi(Peter MacCallum Cancer Centre), Giuseppe Curigliano(European Institute of Oncology), Roberto Salgado(GZA Ziekenhuizen Campus Sint-Augustinus), Roberto Iván Romero Díaz, Suzette Delaloge(Institut Gustave Roussy), C. Rojas, Marleen Kok(The Netherlands Cancer Institute), C. Saura Manich(Vall d'Hebron Hospital Universitari), Nadia Harbeck(Ludwig-Maximilians-Universität München), Elizabeth A. Mittendorf(Dana-Farber Brigham Cancer Center), Denise A. Yardley(Tennessee Oncology), Lajos Pusztai(Smilow Cancer Hospital), Alberto Suárez Zaizar, Aurelian Ungureanu, Felipe Ades(Bristol-Myers Squibb (United States)), R. Chandra(Bristol-Myers Squibb (United States)), Raheel Nathani(Bristol-Myers Squibb (United States)), Misena Pacius(Bristol-Myers Squibb (United States)), Jintong Wu(Bristol-Myers Squibb (United States)), Heather L. McArthur(The University of Texas Southwestern Medical Center)
Cited by 103Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis